3.53
price up icon10.66%   0.34
after-market アフターアワーズ: 3.52 -0.010 -0.28%
loading

Immuneering Corp (IMRX) 最新ニュース

pulisher
Jun 18, 2025

Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com

Jun 18, 2025
pulisher
Jun 18, 2025

Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Asianet Newsable

Jun 18, 2025
pulisher
Jun 17, 2025

Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering stock rises after positive pancreatic cancer trial data - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan

Jun 17, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering Corp holds annual stockholder meeting - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World

Jun 12, 2025
pulisher
Jun 06, 2025

Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus

Jun 05, 2025
pulisher
May 29, 2025

Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 15, 2025

‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail

May 15, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World

May 07, 2025
pulisher
May 07, 2025

Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks

May 07, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks

May 06, 2025
pulisher
May 06, 2025

Immuneering (IMRX) Stock Rating and Price Target Update | IMRX Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Immuneering Corp SEC 10-Q Report - TradingView

May 05, 2025
pulisher
May 05, 2025

Immuneering Reports Breakthrough: Cancer Drug Achieves 13-Month Survival in Late-Stage Pancreatic Cancer Patient - Stock Titan

May 05, 2025
pulisher
May 04, 2025

IMRXImmuneering Corp Latest Stock News & Market Updates - Stock Titan

May 04, 2025
pulisher
May 01, 2025

Charting the Course: Immuneering Corp’s IMRX Stock Prospects - investchronicle.com

May 01, 2025
pulisher
May 01, 2025

What technical indicators reveal about IMRX stock - uspostnews.com

May 01, 2025
pulisher
Apr 30, 2025

Immuneering Co. (NASDAQ:IMRX) Short Interest Update - Defense World

Apr 30, 2025
pulisher
Apr 05, 2025

Immuneering Co. (NASDAQ:IMRX) Shares Bought by HighTower Advisors LLC - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Full Executive Team Reveals Next Growth Phase at Major Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Mar 28, 2025

Chardan Capital Weighs in on Immuneering FY2025 Earnings - Defense World

Mar 28, 2025
pulisher
Mar 23, 2025

Immuneering’s (IMRX) “Buy” Rating Reaffirmed at Needham & Company LLC - The AM Reporter

Mar 23, 2025
pulisher
Mar 23, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX) - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Immuneering Corp. Reports Promising Cancer Trial Results - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Immuneering Strengthens Leadership: New CMO Joins with $212K Stock Option Grant - StockTitan

Mar 21, 2025
pulisher
Mar 20, 2025

Immuneering reports Q4 EPS (58c), consensus (44c) - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corp SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Corporation Q4 Net Income USD 18.1 Million -March 20, 2025 at 04:54 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering Breakthrough: New Cancer Drug Doubles Standard Treatment Success Rate - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints Igor Matushansky as CMO - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Immuneering appoints new Chief Medical Officer - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Former Ipsen Executive Who Led FDA-Approved Cancer Drug Joins Immuneering as CMO - Stock Titan

Mar 20, 2025
pulisher
Mar 05, 2025

Immuneering Slides As Insider Purchases Lose Another US$186k - Yahoo Finance

Mar 05, 2025
pulisher
Mar 03, 2025

Brokerages Set Immuneering Co. (NASDAQ:IMRX) Target Price at $12.20 - Armenian Reporter

Mar 03, 2025
pulisher
Mar 03, 2025

Immuneering Co. (NASDAQ:IMRX) Receives $12.20 Consensus PT from Analysts - Defense World

Mar 03, 2025
pulisher
Feb 28, 2025

Immuneering (IMRX) Expected to Announce Quarterly Earnings on Friday - Defense World

Feb 28, 2025
pulisher
Feb 18, 2025

Revolutionary Cancer Treatment Patent: Avalon's Dual-Target CAR-T Therapy Gets China's Green Light - Stock Titan

Feb 18, 2025
pulisher
Feb 14, 2025

Alkermes (NASDAQ:ALKS) & Immuneering (NASDAQ:IMRX) Head to Head Contrast - Armenian Reporter

Feb 14, 2025
pulisher
Feb 10, 2025

Needham & Company LLC Reaffirms "Buy" Rating for Immuneering (NASDAQ:IMRX) - MarketBeat

Feb 10, 2025
pulisher
Feb 07, 2025

Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from Analysts - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Immuneering and Regeneron partner on lung cancer trial - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Immuneering and Regeneron partner on lung cancer trial By Investing.com - Investing.com UK

Feb 06, 2025
pulisher
Feb 06, 2025

Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan

Feb 06, 2025
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
大文字化:     |  ボリューム (24 時間):